Navigation Links
Study Results Show That Minimally Invasive Therapy is Successful for Over Two-Thirds of Stroke Patients Treated Outside the Standard Eight-Hour Window
Date:7/30/2009

ion to pursue our hypothesis," said Nogueira. "Traditionally, these patients had been deemed untreatable. But if the therapeutic window could be expanded, these findings could make a significant impact on the future of stroke treatment."

The study included a consecutive case series of 237 patients whose first angiography (a diagnostic test that infuses the blood vessels with dye in order to clearly visualize the vessel structures) confirming a clot in the brain was performed later than eight hours from the last time the patient was seen well. All patients were identified from prospectively acquire databases at 10 high volume academic stroke centers across the United States.

Of the 237 study participants, 49 percent were males and 51 percent were females, with a mean (or average) age of 64 years and whose mean time from last seen well to t reatment was 15 hours. On the standard National Institute of Health Stroke Scale (NIHSS) -- a test that uses baseline data to determine severity of a stroke and projected outcome -- participants registered a mean score of 15 (any score over 10 is associated with a serious stroke). Various endovascular treatments were used, including: clot-dissolving drugs in 46 percent of the cases; the MERCI Retriever, a clot-removal device, in 62 percent of cases; and other mechanical instruments, including the recently FDA-approved Penumbra Device, in 36 percent of cases.

Beyond the immediate results that showed an overwhelming success in restoring blood flow, follow-up at 90 days in 198 patients indicate that 93 (47 percent) patients registered good outcomes (meaning patients could be functionally independent) and 123 (62 percent) patients reflected acceptable outcomes. Approximately nine percent suffered a symptomatic brain hemorrhage and the overall mortality rate was 22 percent. When analyzing what factors were most closely associated with favorable outcomes, succ
'/>"/>

SOURCE Society of NeuroInterventional Surgery
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy
2. Cyberonics Provides Update on Depression Post-Approval Study
3. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
4. R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
5. UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPars Investigational Cancer Drug BSI-201
6. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
7. Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study
8. Prospective Clinical Advantages of Trabecular Metal(TM) Technology Highlighted in Comparative Study
9. New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed
10. Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
11. Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... IRVINE, Calif. , Oct 22, 2014 ... Irvine, California , announced the receipt ... Small Business Innovation Research award (SBIR) from the National Institute of ... will fund the development of a Pan-HIV Protein Microarray ... the HIV-1 and HIV-2 subtypes and aid in the ...
(Date:10/22/2014)... Oct. 22, 2014  Paper Pak Industries, a ... APLS ® Body Guard Bio, a disposable, ... of bacteria and virus while protecting service providers ... Bio features a rugged, external nylon shell, watertight ... a leak-proof inner chamber that contains contaminated and ...
(Date:10/22/2014)... , Oct. 22, 2014  With a ... animal health medications, a Global Pharmaceutical and Biotech ... serialization technology and turnkey solution to protect their ... http://photos.prnewswire.com/prnh/20141021/153438 Photo - ... that was serialized and aggregated by the Xyntek ...
Breaking Medicine Technology:Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Xyntek and Antares Serialization Solution Protects Pets Too! 2
... 30 Shire plc (LSE: SHP, ... announced findings at a major medical meeting from a Phase ... Daytrana ® (methylphenidate transdermal system) in adolescents aged 13 ... ). In addition, data regarding the pharmacokinetic profile ...
... , SAN DIEGO, Oct. 30 Gen-Probe Incorporated (Nasdaq: ... the Oppenheimer 20th Annual Healthcare Conference in New York on ... at the Lazard Capital Markets 6th Annual Healthcare Conference in ... Eastern time. The presentations are scheduled to be webcast ...
Cached Medicine Technology:Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 2Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 3Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 4Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 5Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 6Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 7Gen-Probe to Webcast Two Upcoming Investor Presentations 2
(Date:10/22/2014)... 22, 2014 Isabel Healthcare ... Health Professions (ASAHP) Conference on October 22-24 in Las ... participate in a panel discussion on Technology in Health ... Healthcare provides a diagnostic decision support tool and clinical ... skills of students and clinical learners. The Isabel tools ...
(Date:10/22/2014)... 2014 The Louis W. ... dedicated to distribute health information technology innovation to ... announced the development of six key guiding principles ... receiving healthcare. These are an expansion of the ... care that is respectful of and responsive to ...
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a ... of bacterial infections, microbial biofilms, and chronic wounds, announced ... of directors. , Dr. Sinskey is ... Massachusetts Institute of Technology, or MIT. He has been ... Sinskey also holds positions as Co-Director of the Malaysia-MIT ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. ... in vitro fertilization (IVF) -- the incubation of embryos in ... device inside the vagina, new research suggests. Scientists from ... an INVOcell, might sharply cut costs for pricey IVF procedures ... accessible to those who don,t live near big-city assisted reproduction ...
Breaking Medicine News(10 mins):Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... Dendreon Corporation (Nasdaq:,DNDN) will release its third quarter financial ... conference call at 1:30,p.m. PT; 4:30 p.m. ET to review ... discussion may be obtained as follows: Time: ... November 15, 2007 Dial-in: ...
... 17th U.S. Surgeon General Richard H. Carmona Joins ... Says Report Findings May Open,Doors to Positive Change, ... and Prevent (STOP) Obesity Alliance today received a ... obesity in America:,unrealistic definitions of success, negative perceptions ...
... ARLINGTON, Va., Nov. 2 FBR Capital Markets,Corporation ... that,Christopher Warren has joined FBR Capital Markets as a ... group and will,focus on the medical device sector. ... research, and we,value the disciplined, rigorous method he,s developed ...
... dexamethasone contributes to a relentless fatigue and poor quality ... leukemia (ALL), according to a new study from St. ... could improve the quality of life for these children ... or eliminate these side effects. , The St. ...
... ... Options, WASHINGTON, Nov. 2 Today, the Society ... interventional cardiology, announced the,launch of Seconds Count, a patient ... authoritative resource about cardiovascular disease and,treatment. The program will ...
... Duane Reade Holdings, Inc. today,announced that on Thursday, November ... results before the open of the market. In ... conference,call on Thursday, November 8, 2007 at 10:00 a.m. ... Officer, and John Henry,Senior Vice President and Chief Financial ...
Cached Medicine News:Health News:-Dendreon to Hold Conference Call on Thursday, November 15, 2007 at 4:30 PM ET- 2Health News:New Academic Analysis Identifies Three Barriers to Achieving Healthy and Achievable Policies to Combat Obesity in America 2Health News:New Academic Analysis Identifies Three Barriers to Achieving Healthy and Achievable Policies to Combat Obesity in America 3Health News:FBR Capital Markets Hires Senior Healthcare Analyst 2Health News:St. Jude finds anti-leukemia drug increases patient fatigue 2Health News:New Web Site Helps Patients Navigate Heart Disease Treatment Options 2Health News:New Web Site Helps Patients Navigate Heart Disease Treatment Options 3
Provides extended cold therapy to the shoulder area for acute, chronic, or post-surgical applications. The DuraKold products can help reduce pain, edema, and speed recovery....
Provides continuous cold therapy to the knee area for acute, chronic, or post-surgical applications. Cryotherapy can reduce pain, swelling and facilitate faster rehabilitation....
... Halo™ was designed in 1988 as an attachment ... patient, it greatly restricts rotation of the cervical ... Halo can be removed while allowing the Collar ... used in conjunction with the Philadelphia Stabilizer attachment., ...
... cold therapy Gel Pad. Our Gel Pad helps ... to reduce swelling and /or hot therapy to ... order hot and cold therapy gel pad, place ... suspenders can be added to each support upon ...
Medicine Products: